The following clinical studies are recruiting patients at UW Veterinary Care. For more information, please visit our website or call Amanda Brooks, clinical research technician, at 608-890-3484. Thank you for helping improve the health of animals.

- **Dermatology**
  - Dogs with Recurrent *Pyoderma* – evaluate efficacy of staphylococcal vaccine (currently on hold)

- **General Surgery**
  - Dogs undergoing surgery for *Laryngeal Paralysis* – evaluate EMG and stimulation responsiveness
  - Dogs with *Mast Cell Tumors >2cm* – compare samples from punch biopsy to whole tumor specimen

- **Genetics**
  - Dogs (any breed) with *Laryngeal Paralysis* and pure-bred *Labrador Retrievers & Golden Retrievers* older than 11 years of age without Laryngeal Paralysis – investigate genetic heritability
  - *Labrador Retrievers & Rottweilers* with and without *Cruciate Disease* – investigate genetic heritability. Note: unaffected dogs over 8 years of age needed as controls

- **Internal Medicine**
  - Clinically healthy *Greyhounds* – investigate why Greyhounds have higher levels of homocysteine
  - Dogs with *Chronic Gastrointestinal Signs* – investigate necessity of fasting for the gastrointestinal panel
  - Dogs with *Documented Bladder Cancer (TCC)* – investigate environmental risk factors

- **Neurology**
  - Cats with *Seizures* – evaluate cause and effect of seizures on the brain in cats following euthanasia
  - Dogs with *Seizures* – evaluate cause and effect of seizures on the brain in dogs following euthanasia

- **Oncology**
  - Cats and Dogs *with and without Cancer* – evaluate accuracy of canine scent detection to identify cancer
  - Dogs with *Any Cancer* – evaluate palladia in combination with doxorubicin
  - Cats with *Any Cancer* – evaluate safety of meloxicam in combination with toceranib phosphate
  - Dogs with *Anal Sac Adenocarcinoma* – evaluate the effect of conformal hypofractionated radiotherapy
  - Dogs with *Any Malignant Tumor (except lymphoma or leukemia)* – evaluate a novel approach to stimulate the dog’s own immune cells to fight against the dog’s tumor
  - Dogs with *Any Malignant Tumor (except mast cell tumor or hemangiosarcoma)*—evaluate a novel anticancer drug that is administered orally
  - Dogs with *Documented Bladder Cancer (TCC)* – investigate environmental risk factors
  - Dogs with *Melanoma* – evaluate a combination of new immune therapy approaches with radiation therapy
  - Dogs with *Metastatic Melanoma* – evaluate an intravenous, targeted radiation treatment combined with an immunotherapy treatment
  - Dogs with *Nasal Tumors* – evaluate the effect of radiotherapy on oral health in dogs
  - Dogs with *Newly Diagnosed Lymphoma* – evaluate the addition of the first FDA-approved drug for canine lymphoma (Tanovea) to the standard-of-care chemotherapy protocol
  - Dogs *without Cancer, Ages 6-11* – may qualify for a 5-year study evaluating a vaccine against canine cancers

- **Ophthalmology**
  - *Siberian Huskies* 10+ years old or with a history of glaucoma – investigate genetic basis of glaucoma